Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast

After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to its blockbuster ambitions will hit a stride in 2026, when it expects | The company doubled sales of its Biogen-partnered Alzheimer's disease treatment during its 2025 fiscal year.

Raccontata dafiercepharma.com